Physician profile
David Cahn
NPI 1689762205
$39,800.42
in general payments reported to CMS, 2019-2025
86 companies · $4,389 in 2025
The $4,389 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,727 · 2020: $2,672 · 2021: $3,875 · 2022: $3,946 · 2023: $9,078 · 2024: $11K · 2025: $4,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,000 · Travel and Lodging: $772 · Education: $92.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,717.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,000.00 |
| Travel and Lodging | $771.75 |
| Education | $92.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12,094.65 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $4,058.68 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,998.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,641.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,637.38 | 2019-2025 | |
| Novo Nordisk INC | $1,542.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $1,322.79 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Janssen Research & Development, LLC | $1,165.40 | 2019 | |
| Lilly USA, LLC | $929.46 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $904.99 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $881.10 | 2020-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $827.38 | 2019-2025 | Jardiance |
| Mylan Specialty L.P. | $784.62 | 2019-2024 | Yupelri |
| Radius Health, INC. | $726.09 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $675.60 | 2019-2024 | Verquvo, Belsomra, Januvia |
Show all 86 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.